Heart failure affects approximately one million individuals in the UK, with an estimated 200,000 new cases diagnosed annually. Of these, around 50,000 patients are classified as having advanced heart failure and are under 65 years old, thereby potentially qualifying for interventions aimed at prolonging survival and improving quality of life. Yet the audit’s findings reveal a stark underutilization of these therapies, with only slightly over 300 surgical interventions reported annually throughout the UK. This shortfall is alarming given the substantial morbidity and mortality associated with advanced heart failure, and underscores the urgent need for refined national strategies to bridge this service delivery gap.

The audit specifically scrutinized referral trends to the seven adult heart transplant centers spanning the UK and Ireland, focusing on patients referred for heart transplant or LVAD assessment within the first four months of 2024. The study employed a granular approach by stratifying referral regions based on rates per million population within the key eligibility age group of 16 to 69 years. This detailed regional analysis exposed dramatic disparities, with referral rates varying from below three per million to over thirty per million, after appropriate adjustment for the population’s age profile. Such heterogeneity suggests that local clinical practices and institutional referral cultures may play a more decisive role than demographic or socioeconomic factors.

One of the most concerning revelations of the audit is the persistent under-referral of women for advanced heart failure therapies. Women accounted for only approximately one-third of referrals, even though epidemiological data suggest a comparable disease burden between sexes. The underrepresentation of women hints at systemic biases or gaps in clinician awareness that disadvantage female patients, thus compounding health inequities. Addressing this gender disparity will require concerted efforts to standardize referral criteria, enhance clinician education, and raise public awareness about the eligibility and benefits of life-prolonging treatments for heart failure.

Further complicating the landscape is the finding that nearly one-third of patients referred for assessment were deemed unsuitable for advanced therapies at the point of evaluation. The primary reasons included modifiable contraindications such as poorly controlled diabetes, ongoing tobacco or alcohol use, and frailty. These factors highlight missed opportunities for earlier intervention and optimization of patient health prior to referral. They also underscore the critical importance of integrated care pathways that emphasize comprehensive management of comorbidities and lifestyle modification in patients with heart failure, optimizing their candidacy for advanced therapeutic modalities.

Importantly, the audit found no significant relationship between proximity to transplant centers and the likelihood of referral, nor did it observe an association with the level of deprivation as derived from patient postcode analyses. This finding challenges preconceived notions about access barriers rooted in geography or socioeconomic status and instead implicates elements intrinsic to healthcare delivery systems—such as clinician referral behavior, regional health service organization, and resource allocation—as key drivers of the observed disparities. Given that postcode-level socioeconomic data may imperfectly capture individual patient circumstances, the report acknowledges the need for deeper data granularity to fully elucidate underlying causes.

The report’s authors emphasize that the current findings reflect broader systemic issues, including a pronounced lack of standardization in specialist heart failure services across the UK and Ireland. While some regions demonstrate robust, well-resourced programs with streamlined referral pathways, others are characterized by fragmented or absent services, contributing to inconsistent patient experiences and outcomes. This uneven landscape poses challenges for national healthcare planning, necessitating coordinated policy frameworks that promote equitable access, workforce development, and resource distribution tailored to population needs.

Despite certain limitations—such as reliance on regional postcode data and incomplete capture of the full continuum of care—the audit sets a powerful precedent for ongoing surveillance and quality improvement in advanced heart failure management. The authors call for development and widespread adoption of standardized, co-produced referral criteria, enhanced educational initiatives targeting clinicians, and the fostering of collaborative networks that transcend national and devolved healthcare boundaries. Such strategies aim to ensure timely identification and optimal management of eligible patients, thereby maximizing therapeutic benefit and survival.

The clinical implications extend beyond mere referral counts. Given epidemiological estimates suggesting around 134,000 individuals in the UK may be living with advanced heart failure, many requiring specialist palliative care in addition to life-prolonging interventions, the audit highlights a vast unmet need within this patient population. Ensuring access to comprehensive, multidisciplinary care must be a central priority, integrating cardiology, palliative services, and community support to holistically address symptom burden, quality of life, and end-of-life planning.

Dr. Rajiv Sankaranarayanan of the British Cardiovascular Society encapsulates the urgency of these findings, emphasizing the ethical imperative to rectify inequities in access to advanced therapies. He advocates for national standardization of referral pathways and infrastructure enhancement to guarantee that potentially life-saving treatments are accessible regardless of geographical locale or patient sex. The report’s resounding message is a call to action: to align clinical practice with evidence-based standards and equity principles, thus transforming the landscape of advanced heart failure care in the UK and Ireland.

In sum, this first-of-its-kind national audit reveals profound inter-regional and demographic disparities in the referral and utilization of advanced heart failure therapies, illuminating critical areas for intervention. By addressing modifiable contraindications earlier in the disease course, standardizing referral practices, and expanding specialist service provision across regions, healthcare systems can improve prognosis and equity for this vulnerable patient group. The audit provides a foundational evidence base for future research, policy formulation, and clinical innovation aimed at optimizing outcomes for patients with advanced heart failure.

Subject of Research: People
Article Title: Overview of findings from the UK and Ireland National Advanced Heart Failure Audit 2024
News Publication Date: 2-Jun-2026
Web References: http://dx.doi.org/10.1136/openhrt-2025-003909
Keywords: Cardiology, Heart failure, Health disparity

Historically, sudden cardiac death has been characterized by its abrupt onset, often occurring without prior warning signs or critical deterioration. However, the current analysis challenges this paradigm by demonstrating that patients destined to experience sudden death frequently manifest subtle but measurable clinical worsening. Notably, symptoms intensify modestly, patients’ quality of life deteriorates, and levels of circulating natriuretic peptides—biochemical markers of cardiac stress—increase in the weeks leading up to the fatal event. These markers have long been implicated in heart failure pathophysiology, serving as valuable tools for both diagnosis and prognosis.

The FINEARTS-HF trial cohort, drawn from contemporary clinical populations with HFmrEF and HFpEF, provides an ideal substrate for investigating sudden death dynamics. These groups have historically been underrepresented in heart failure research, which has predominantly focused on those with reduced ejection fraction (HFrEF). Given the distinct pathophysiological mechanisms and less clearly defined treatment protocols for HFmrEF and HFpEF, understanding the precursors to sudden death within this demographic addresses a critical unmet need in cardiovascular medicine.

Using a battery of rigorous longitudinal assessments, researchers quantified patient-reported symptom severity alongside objective biomarker profiles. This dual approach enabled them to correlate subjective clinical experiences with measurable biochemical evidence of cardiac strain. Importantly, rising natriuretic peptide levels emerged as a consistent harbinger of imminent mortality risk, corroborating prior studies yet adding granularity regarding timing and severity. The gradual deterioration challenges the notion that sudden death is purely an unheralded event and instead suggests a window of opportunity for intervention.

Intriguingly, the study also reports that similar pre-mortem clinical deterioration occurred in patients who succumbed to other modes of death, such as progressive heart failure or non-cardiovascular causes. This observation highlights the complexity of differentiating sudden cardiac death from other fatal trajectories based solely on symptomatology and biomarkers. Therefore, although the patterns of worsening offer important clues, their specificity for sudden death events remains limited, underscoring the necessity for more refined predictive models.

Clinicians managing patients with HFmrEF and HFpEF may need to rethink risk stratification frameworks in light of these findings. Continuous monitoring of natriuretic peptide trends and symptom burden could provide valuable real-time data to identify those at risk for fatal arrhythmias or cardiac arrest. This approach contrasts with current strategies that rely heavily on static measures like ejection fraction or historical events. Personalized surveillance protocols incorporating dynamic biomarker changes could revolutionize care by enabling anticipatory interventions.

Mechanistically, the findings invite deeper exploration into the pathophysiological cascade underpinning sudden death in heart failure populations with preserved or mildly reduced ejection fractions. Unlike HFrEF, where ventricular remodeling and systolic dysfunction have been extensively characterized, HFpEF and HFmrEF involve complex diastolic abnormalities, microvascular dysfunction, and systemic inflammation. The progressive rise in natriuretic peptides might reflect increasing myocardial wall stress, fluid overload, or neurohormonal activation that collectively destabilize cardiac electrophysiology, precipitating lethal arrhythmias.

Future research trajectories may focus on integrating advanced imaging modalities, electrophysiological monitoring, and biomarkers to build comprehensive risk profiles before sudden death occurs. Additionally, the modest symptom worsening documented prior to fatal events suggests that leveraging patient-reported outcomes combined with wearable technologies could empower patients and providers alike. By capturing early signals of decompensation, clinicians may deploy tailored therapies such as device implantation or pharmacological modulation to avert catastrophic outcomes.

These revelations emerge in the broader context of evolving paradigms about heart failure phenotypes and their mortality risks. With the American College of Cardiology spotlighting these results at its 75th Annual Scientific Session & Expo, the clinical community is poised to engage in robust debate over redefining sudden death definitions and prevention tactics. Incorporating these insights into guidelines could enhance survival in a population historically challenged by therapeutic limitations and diagnostic uncertainties.

In sum, the FINEARTS-HF post hoc analysis elucidates a critical dimension of sudden death in contemporary heart failure populations that warrants urgent clinical and scientific attention. By mapping the subtle yet discernible clinical and biochemical deterioration preceding fatal events, this study paves the way toward more effective risk identification and preemptive care strategies. As the understanding of heart failure pathophysiology deepens, so too does the potential to transform sudden death from a feared inevitability to a preventable endpoint.

The work was led by corresponding author Dr. Scott D. Solomon at Brigham and Women’s Hospital, whose pioneering efforts continue to advance the field of cardiovascular therapeutics. The full study is available in JAMA Cardiology and offers extensive data on symptom trajectories, biomarker kinetics, and methodological rigor in assessing sudden death phenomena. Importantly, while the study clarifies many aspects of mortality patterns, it also leaves fertile ground for future inquiry into the mechanisms that differentiate sudden death from other lethal heart failure outcomes.

These findings compel a reexamination of patient monitoring frameworks, clinical decision-making, and therapeutic approaches in HFmrEF and HFpEF. Embracing a dynamic view of disease progression rather than static risk assessments aligns with the broader movement toward precision medicine in cardiology. Ultimately, the integration of these novel insights may reduce sudden death incidence, improve quality of life, and extend survival in this vulnerable patient population, marking a significant milestone in heart failure management.

Subject of Research: Sudden death and preceding clinical deterioration in heart failure with mildly reduced or preserved ejection fraction.

Article Title: Not specified in provided content.

News Publication Date: Not specified in provided content.

Web References: doi:10.1001/jamacardio.2026.0682

References: See original JAMA Cardiology article.

Image Credits: Not specified in provided content.

Keywords: Heart failure, HFmrEF, HFpEF, sudden death, natriuretic peptides, clinical deterioration, biomarkers, cardiovascular mortality, FINEARTS-HF trial, risk stratification, cardiology, arrhythmia prevention.

In recent years, attention has shifted towards the role of skeletal muscle health in various medical conditions, including cardiovascular diseases. Skeletal muscle viscoelasticity serves as a promising biomarker indicative of muscular health and function. In older adults, decreased muscle mass and altered muscle composition can lead to significant implications for mobility, strength, and overall quality of life. The VISMARC-HF study aims to explore these connections comprehensively, highlighting the importance of muscle properties in understanding heart failure prognosis.

One intriguing aspect of the study is its focus on the biomechanical properties of skeletal muscle, particularly viscoelasticity. This characteristic describes how muscle behaves under stress, combining both elastic and viscous responses. Changes in viscoelasticity can signify underlying pathological processes, such as sarcopenia, inflammation, and other age-related muscular changes. By investigating these parameters, the researchers aim to establish a correlation that may pave the way for new assessment tools in clinical settings.

Investigators plan to recruit older heart failure patients at various stages, examining their skeletal muscle properties using advanced imaging and biomechanical testing techniques. This meticulous approach will allow for a thorough characterization of muscle viscoelasticity and its potential prognostic indicators. Evaluating both the strength and elasticity of muscle tissues can provide insights into patient resilience, response to therapies, and overall survival rates.

Moreover, the significance of understanding skeletal muscle viscoelasticity lies in its potential application for personalized medicine. As healthcare providers increasingly focus on individualized treatment regimens, integrating muscle analysis into routine evaluations can help identify at-risk patients proactively. If a strong prognostic link is established, clinicians may be better equipped to tailor interventions aimed at enhancing muscle function, thereby potentially improving heart failure outcomes.

The VISMARC-HF study not only aims to elucidate the relationship between muscle viscoelasticity and heart failure but also strives to enhance our understanding of the broader context of aging and cardiovascular health. As older adults represent a growing demographic, the implications of this research reach far beyond individual patient care. By shedding light on the interplay between muscle health and heart function, this study could contribute to public health strategies aimed at managing the growing burden of heart failure in the elderly population.

Initiating this research requires careful consideration of methodological aspects. The integration of diverse assessment tools—from muscle biopsies to advanced imaging modalities—demands rigorous planning and execution. Researchers will rely on cutting-edge technology and interdisciplinary collaboration to ensure that the data collected is both robust and reliable. This ambitious approach underscores the researchers’ commitment to maximizing the study’s impact within the scientific community.

With heart failure diagnosis often accompanied by a myriad of comorbidities, it is essential to establish precise measures that can delineate the unique contributions of skeletal muscle viscoelasticity. For instance, the interplay between muscle health, physical activity levels, and metabolic status may reveal critical insights into patient-specific disease trajectories. By disentangling these associations, the future of heart failure management can be informed by an integrative understanding of muscle and cardiovascular physiology.

Additionally, the implications of this research extend to preventive strategies as well. The potential for early identification of at-risk individuals based on their skeletal muscle assessments could enable the implementation of targeted exercise and rehabilitation programs. Fostering muscle strength and flexibility through tailored physical activity regimens can be vital in mitigating the risk of heart failure progression and enhancing patients’ overall well-being.

The ultimate goal of the VISMARC-HF study transcends mere academic exploration; it aims to forge a path towards actionable clinical applications that can make a tangible difference in the lives of older adults experiencing heart failure. With a focus on enhancing life quality and promoting longevity, the results of this investigation could resonate far beyond the immediate clinical implications and into broader societal frameworks.

As the study unfolds, the medical community eagerly anticipates the findings that will emerge. The convergence of geriatrics, cardiology, and muscle health presents an exciting frontier in research that promises to illuminate the complexities of aging and disease management. With stakeholders invested in advancing geriatric care, the VISMARC-HF study stands as a beacon of hope, inspiring continued inquiry and innovation in the realm of heart health.

Ultimately, the journey towards understanding the prognostic value of skeletal muscle viscoelasticity in older adults with heart failure exemplifies the collaborative efforts of researchers committed to improving health outcomes through rigorous scientific inquiry and innovative approaches. As the study progresses, it brings with it the potential to reshape clinical practices and inform policies aimed at enhancing the quality of life for our aging population, leading the way toward healthier futures.

In summary, the VISMARC-HF study is set to delve deeply into the intricate relationship between skeletal muscle viscoelasticity and prognostic outcomes in older patients experiencing heart failure, shedding light on this crucial aspect of geriatric care. The implications of this study have the potential to transform how healthcare professionals approach treatment for heart failure in older adults, emphasizing the need for a comprehensive understanding of muscle health in this demographic.

Subject of Research: Skeletal Muscle Viscoelasticity in Older Patients with Heart Failure

Article Title: Prognostic value of skeletal muscle viscoelasticity in older patients with heart failure: the VISMARC-HF study design.

Article References: Nagaoka, R., Katano, S., Yano, T. et al. Prognostic value of skeletal muscle viscoelasticity in older patients with heart failure: the VISMARC-HF study design. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07016-6

Image Credits: AI Generated

DOI: 10.1186/s12877-026-07016-6

Keywords: skeletal muscle viscoelasticity, heart failure, aging, geriatric health, prognosis, muscle assessment